- ISIN
- US6036931029
- CUSIP
- 603693102
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Oct 15, 2021
Highlights
- EPS (TTM)
- -$2.93
- Gross Profit (TTM)
- -$197.05K
- EBITDA (TTM)
- -$12.16M
- Year Range
- $6.80 - $76.00
- Target Price
- $35.00
- ROA (TTM)
- -0.09%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
INKT Performance Chart
MiNK Therapeutics, Inc. (INKT) is up 9.9% since the beginning of the year. At $12 per share, INKT is trading 83.9% below its 52-week high of $76.
Loading charts...
Returns By Period
MiNK Therapeutics, Inc. (INKT) has returned 9.87% so far this year and 68.73% over the past 12 months.
MiNK Therapeutics, Inc.
- 1D
- 0.91%
- 1M
- 12.70%
- YTD
- 9.87%
- 6M
- 5.06%
- 1Y
- 68.73%
- 3Y*
- -21.78%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
INKT Monthly Returns History
Based on dividend-adjusted daily data since Oct 15, 2021, INKT's average daily return is +0.52%, while the average monthly return is -1.17%.
Historically, 32% of months were positive and 68% were negative. The best month was Jul 2025 with a return of +105.2%, while the worst month was Dec 2021 at -61.6%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 9 months.
On a daily basis, INKT closed higher 44% of trading days. The best single day was Jul 11, 2025 with a return of +730.1%, while the worst single day was May 1, 2023 at -39.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 5.65% | -7.05% | -3.84% | 15.86% | 0.00% | 0.41% | 9.87% | ||||||
| 2025 | 31.44% | -2.29% | -3.46% | -13.75% | -5.66% | 5.09% | 105.21% | -6.07% | -1.69% | 0.29% | -25.14% | 6.09% | 59.99% |
| 2024 | -19.16% | 6.51% | -1.41% | 8.99% | -2.02% | -2.14% | -0.97% | -13.83% | -7.41% | -4.80% | 2.66% | -4.92% | -34.87% |
| 2023 | -12.39% | -11.22% | -6.65% | -5.54% | -1.68% | 19.32% | -10.95% | -22.46% | -24.14% | -7.27% | 2.94% | 1.90% | -59.00% |
| 2022 | -26.23% | -9.73% | -24.24% | -0.44% | -30.80% | -9.03% | -7.09% | 100.76% | -19.77% | 3.32% | 21.56% | -1.51% | -41.48% |
| 2021 | 48.59% | -35.16% | -61.55% | -62.96% |
Benchmark Metrics
MiNK Therapeutics, Inc. has an annualized alpha of 243.44%, beta of 0.51, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since October 15, 2021.
- This stock participated in 151.93% of S&P 500 Index downside but only -41.42% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.51 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 243.44%
- Beta
- 0.51
- R²
- 0.00
- Upside Capture
- -41.42%
- Downside Capture
- 151.93%
Return for Risk
Risk / Return Rank
INKT ranks 71 for risk / return — better than 71% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for MiNK Therapeutics, Inc. (INKT) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| INKT | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.94 | ||
| Sortino ratioReturn per unit of downside risk | +5.79 | ||
| Omega ratioGain probability vs. loss probability | 2.13 | 1.37 | +0.76 |
| Calmar ratioReturn relative to maximum drawdown | 0.80 | 2.78 | -1.99 |
| Martin ratioReturn relative to average drawdown | 0.89 | 12.44 | -11.55 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the MiNK Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the MiNK Therapeutics, Inc. was 97.69%, occurring on Dec 18, 2024. The portfolio has not yet recovered.
The current MiNK Therapeutics, Inc. drawdown is 93.88%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2024 bear market2024 | -97.69%Dec 2024 | 3y 1mo | — | 4y 7moNov 2021 - now |
2021 correction2021 | -12.71%Nov 2021 | 2d | 6d | 8dNov 2021 - Nov 2021 |
2021 pullback2021 | -4.77%Oct 2021 | 3d | 2d | 5dOct 2021 - Oct 2021 |
2021 pullback2021 | -2.82%Oct 2021 | 3d | 1d | 4dOct 2021 - Oct 2021 |
Drawdown Indicators
| INKT | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.69% | -56.78% | -40.91% |
Max Drawdown (1Y)Largest decline over 1 year | -86.66% | -9.10% | -77.56% |
Max Drawdown (3Y)Largest decline over 3 years | -86.66% | -18.90% | -67.76% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -93.88% | -1.80% | -92.08% |
Average DrawdownAverage peak-to-trough decline | -89.98% | -10.71% | -79.27% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 77.56% | 2.03% | +75.53% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of MiNK Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how MiNK Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with INKT
Add MiNK Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with INKT